As part of the deal, Lilly will make certain volumes of its antibody therapies available to lower-income countries prior to April 2021. The company said its partners with which it is developing antibody therapies, including Canadian biotech company AbCellera Biologics Inc, had agreed to waive their royalties on the therapies distributed in low- and middle-income countries. Data in September showed that Lilly's single antibody therapy, LY-CoV555, helped cut hospitalization and emergency room visits for COVID-19 patients. A dual-antibody combination also showed similar results on Wednesday. Lilly plans to seek U.S. emergency use authorization for that combination next month.

Source: bd News24 October 08, 2020 11:03 UTC